Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with irritable bowel syndrome

Man-Chin Hua, Hsun-Chin Chao, Tsung-Chieh Yao, Ming-Wei Lai, Jing-Long Huang, PATCH Study Group, Man-Chin Hua, Hsun-Chin Chao, Tsung-Chieh Yao, Ming-Wei Lai, Jing-Long Huang, PATCH Study Group

Abstract

Background/aims: The aim of this study was to investigate whether genetic variations at positions -1082, -819, and -592 in the interleukin (IL)-10 promoter affect IL-10 production in children with irritable bowel syndrome (IBS).

Methods: Ninety-four children with IBS and 102 children as healthy controls (HCs) were enrolled. Genomic DNA was extracted, and IL-10 -1082, -819, and -592 polymorphisms were detected by direct sequencing from all participants. Peripheral blood mononuclear cells (PBMCs) from 46 IBS children and 38 HCs were isolated and cultured with and without 5 ng/mL Escherichia coli lipopolysaccharide (LPS). IL-10 levels in the culture supernatants were measured by enzyme-linked immunosorbent assay.

Results: There were no significant differences in the distribution of IL-10 -1082, -819, and -592 polymorphisms or in the allele and haplotype frequencies between IBS children and HCs. PBMCs from children with IBS had significantly lower IL-10 levels after LPS stimulation than PBMCs from HCs (p=0.011); however, LPS-induced IL-10 levels in PBMCs with different genotypes of -819 and -592 polymorphisms were not significantly different between IBS patients and HCs.

Conclusions: Although significantly lower LPS-induced IL-10 production by PBMCs was noted, it is unlikely that IL-10 production was fully genetically determined in our IBS children. ClinicalTrials.gov identifier: NCT01131442.

Keywords: Child; Interleukin-10; Interleukin-10 gene polymorphisms; Irritable bowel syndrome.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Box plot of interleukin (IL)-10 levels following 5 ng/mL lipopolysaccharide stimulation in irritable bowel syndrome (IBS) subtype and healthy controls diarrhea-predominant IBS [D-IBS]: 1,532.68±870.22 vs. constipation-predominant IBS [C-IBS]: 1,428.39±413.66 vs. mixed IBS [M-IBS]: 2,159.44±265.48 vs. HCs [healthy controls]: 2,521.16±1,046.06 pg/mL). *Statistically significant, p<0.05.
Fig. 2
Fig. 2
Box plot showing that peripheral blood mononuclear cells (PBMCs) from irritable bowel syndrome (IBS) patients tend to produce lower interleukin (IL)-10 levels after stimulation with 5 ng/mL lipopolysaccharide compared to PBMCs from the healthy controls (HCs) group in different genotypes of -819 and -592 polymorphisms. There was no significant difference between the IBS patients and HC group (p=0.101).

References

    1. Wyllie R. Recurrent abdominal pain of childhood. In: Kliegman R, Nelson WE, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders; 2007. p. 1627.
    1. Song GH, Venkatraman V, Ho KY, Chee MW, Yeoh KG, Wilder-Smith CH. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain. 2006;126:79–90.
    1. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411–423.
    1. Locke GR, 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ., 3rd Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75:907–912.
    1. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93:1311–1317.
    1. Solmaz M, Kavuk I, Sayar K. Psychological factors in the irritable bowel syndrome. Eur J Med Res. 2003;8:549–556.
    1. Koloski NA, Talley NJ, Boyce PM. A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion. 2005;72:86–96.
    1. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979–1988.
    1. Dinan TG, Clarke G, Quigley EM, et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol. 2008;103:2570–2576.
    1. Collins SM. Dysregulation of peripheral cytokine production in irritable bowel syndrome. Am J Gastroenterol. 2005;100:2517–2518.
    1. Macsharry J, O'Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467–1476.
    1. Bashashati M, Rezaei N, Andrews CN, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 2012;57:201–209.
    1. Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig. 2010;102:711–717.
    1. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920.
    1. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr. 2011;52:376–381.
    1. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 2003;52:91–93.
    1. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol. 2005;100:2510–2516.
    1. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol. 1994;56:1–26.
    1. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193–197.
    1. Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun. 1999;1:151–155.
    1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):II43–II47.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
    1. Park MI, Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am. 2005;34:305–317.
    1. Barkhordari E, Rezaei N, Mahmoudi M, et al. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation. 2010;33:281–286.
    1. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994;106:533–539.
    1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–2131.
    1. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.
    1. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24:36–43.
    1. Kindt S, Van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21:389–398.
    1. Windle HJ, Ang YS, Athie-Morales V, McManus R, Kelleher D. Human peripheral and gastric lymphocyte responses to Helicobacter pylori NapA and AphC differ in infected and uninfected individuals. Gut. 2005;54:25–32.
    1. Birkholz S, Knipp U, Nietzki C, Adamek RJ, Opferkuch W. Immunological activity of lipopolysaccharide of Helicobacter pylori on human peripheral mononuclear blood cells in comparison to lipopolysaccharides of other intestinal bacteria. FEMS Immunol Med Microbiol. 1993;6:317–324.
    1. Sperber K, Silverstein L, Brusco C, Yoon C, Mullin GE, Mayer L. Cytokine secretion induced by superantigens in peripheral blood mononuclear cells, lamina propria lymphocytes, and intraepithelial lymphocytes. Clin Diagn Lab Immunol. 1995;2:473–477.
    1. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.
    1. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 2000;1:185–190.
    1. Mahdaviani SA, Rezaei N, Moradi B, Dorkhosh S, Amirzargar AA, Movahedi M. Proinflammatory cytokine gene polymorphisms among Iranian patients with asthma. J Clin Immunol. 2009;29:57–62.
    1. Movahedi M, Mahdaviani SA, Rezaei N, Moradi B, Dorkhosh S, Amirzargar AA. IL-10, TGF-beta, IL-2, IL-12, and IFN-gamma cytokine gene polymorphisms in asthma. J Asthma. 2008;45:790–794.
    1. Rezaei N, Aghamohammadi A, Shakiba Y, et al. Cytokine gene polymorphisms in common variable immunodeficiency. Int Arch Allergy Immunol. 2009;150:1–7.
    1. Barkhordari E, Rezaei N, Ansaripour B, et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol. 2010;30:74–79.
    1. Lee HJ, Lee SY, Choi JE, et al. G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:758–763.
    1. Fickenscher H, Hör S, Küpers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol. 2002;23:89–96.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere